id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2008-D-0626-0005,FDA,FDA-2008-D-0626,ViroPharma Incorporated - Request for Extension Comment Due Date,Other,EXT-Request for Extension Comment Due Date,2008-12-22T05:00:00Z,2008,12,2008-12-22T05:00:00Z,,2013-07-27T22:34:03Z,,0,0,09000064807e36f0
FDA-2008-D-0626-0002,FDA,FDA-2008-D-0626,Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl; Guidance,Other,GDL-Guidance (Supporting and Related Materials),2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,,2024-11-12T04:26:03Z,,1,0,09000064807ddb4a
FDA-2008-D-0626-0001,FDA,FDA-2008-D-0626,Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl; Availability,Notice,NAD-Notice of Availability of Data,2008-12-16T05:00:00Z,2008,12,2008-12-16T05:00:00Z,2009-02-18T04:59:59Z,2009-01-23T17:39:34Z,E8-29692,0,0,09000064807dd7fc
FDA-2008-D-0626-0003,FDA,FDA-2008-D-0626,"Report to Office of Generic Drugs - ""Vancomycin Solubility Study"" - [Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl; Guidance] re FDA-2008-D-0626-0002 - Reference",Supporting & Related Material,REF-Reference (internal unless indicated),2008-12-16T05:00:00Z,2008,12,,,2010-11-03T16:20:46Z,,0,0,09000064807ddb61
FDA-2008-D-0626-0004,FDA,FDA-2008-D-0626,"Report to Office of Generic Drugs - ""Vancomycin Dissolution Study"" - [Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl; Guidance] re FDA-2008-D-0626-0002 - Reference",Supporting & Related Material,REF-Reference (internal unless indicated),2008-12-16T05:00:00Z,2008,12,,,2010-11-03T16:24:23Z,,0,0,09000064807ddb72